DE69332861T2 - Neues protein aus urin, komponent b genannt - Google Patents

Neues protein aus urin, komponent b genannt Download PDF

Info

Publication number
DE69332861T2
DE69332861T2 DE69332861T DE69332861T DE69332861T2 DE 69332861 T2 DE69332861 T2 DE 69332861T2 DE 69332861 T DE69332861 T DE 69332861T DE 69332861 T DE69332861 T DE 69332861T DE 69332861 T2 DE69332861 T2 DE 69332861T2
Authority
DE
Germany
Prior art keywords
pct
component
urine protein
new urine
sec
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69332861T
Other languages
English (en)
Other versions
DE69332861D1 (de
Inventor
Antonino Sirna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Serono SA
Original Assignee
Applied Research Systems ARS Holding NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems ARS Holding NV filed Critical Applied Research Systems ARS Holding NV
Publication of DE69332861D1 publication Critical patent/DE69332861D1/de
Application granted granted Critical
Publication of DE69332861T2 publication Critical patent/DE69332861T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE69332861T 1992-12-22 1993-12-21 Neues protein aus urin, komponent b genannt Expired - Fee Related DE69332861T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM920919A IT1257184B (it) 1992-12-22 1992-12-22 Preparato ad attivita' antinfiammatoria, anticoagulante e antitumorale
PCT/EP1993/003645 WO1994014959A1 (en) 1992-12-22 1993-12-21 New protein from urine named component b

Publications (2)

Publication Number Publication Date
DE69332861D1 DE69332861D1 (de) 2003-05-15
DE69332861T2 true DE69332861T2 (de) 2004-01-29

Family

ID=11401349

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69332861T Expired - Fee Related DE69332861T2 (de) 1992-12-22 1993-12-21 Neues protein aus urin, komponent b genannt

Country Status (19)

Country Link
US (1) US5908827A (de)
EP (1) EP0675956B1 (de)
JP (1) JP3025014B2 (de)
KR (1) KR100193107B1 (de)
AT (1) ATE236976T1 (de)
AU (1) AU690093B2 (de)
CA (1) CA2151156A1 (de)
DE (1) DE69332861T2 (de)
DK (1) DK0675956T3 (de)
ES (1) ES2193152T3 (de)
FI (2) FI114478B (de)
IL (1) IL108149A (de)
IT (1) IT1257184B (de)
NO (1) NO315800B1 (de)
PT (1) PT675956E (de)
RU (1) RU2177480C2 (de)
UA (1) UA46702C2 (de)
WO (1) WO1994014959A1 (de)
ZA (1) ZA939621B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001077B1 (ru) * 1996-04-24 2000-10-30 Апплайд Резеч Системз Арс Холдинг Н.В. Компонент в, используемый в качестве рубцующего агента, содержащая его фармацевтическая композиция и способ лечения
WO1998056810A2 (de) * 1997-06-09 1998-12-17 Forssmann Wolf Georg Humanes protein lus-i, seine herstellung und verwendung
ES2184480T3 (es) * 1998-07-09 2003-04-01 Applied Research Systems Componente b como agente angiogenico en combinacion con factores de crecimiento humano.
US6962700B1 (en) * 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
AU2004229237B2 (en) * 2003-04-16 2009-06-04 Merck Serono Sa Use of SLURP-1 for treating diseases related to acetylcholine receptors dysfunction
US7343581B2 (en) * 2005-06-27 2008-03-11 Tela Innovations, Inc. Methods for creating primitive constructed standard cells
US7590968B1 (en) 2006-03-01 2009-09-15 Tela Innovations, Inc. Methods for risk-informed chip layout generation
US8245180B2 (en) 2006-03-09 2012-08-14 Tela Innovations, Inc. Methods for defining and using co-optimized nanopatterns for integrated circuit design and apparatus implementing same
US8839175B2 (en) 2006-03-09 2014-09-16 Tela Innovations, Inc. Scalable meta-data objects
US9009641B2 (en) 2006-03-09 2015-04-14 Tela Innovations, Inc. Circuits with linear finfet structures
US9035359B2 (en) 2006-03-09 2015-05-19 Tela Innovations, Inc. Semiconductor chip including region including linear-shaped conductive structures forming gate electrodes and having electrical connection areas arranged relative to inner region between transistors of different types and associated methods
US8653857B2 (en) 2006-03-09 2014-02-18 Tela Innovations, Inc. Circuitry and layouts for XOR and XNOR logic
US9230910B2 (en) 2006-03-09 2016-01-05 Tela Innovations, Inc. Oversized contacts and vias in layout defined by linearly constrained topology
US8225239B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining and utilizing sub-resolution features in linear topology
US8448102B2 (en) 2006-03-09 2013-05-21 Tela Innovations, Inc. Optimizing layout of irregular structures in regular layout context
US8658542B2 (en) 2006-03-09 2014-02-25 Tela Innovations, Inc. Coarse grid design methods and structures
US8247846B2 (en) 2006-03-09 2012-08-21 Tela Innovations, Inc. Oversized contacts and vias in semiconductor chip defined by linearly constrained topology
US7763534B2 (en) 2007-10-26 2010-07-27 Tela Innovations, Inc. Methods, structures and designs for self-aligning local interconnects used in integrated circuits
US7956421B2 (en) 2008-03-13 2011-06-07 Tela Innovations, Inc. Cross-coupled transistor layouts in restricted gate level layout architecture
US8541879B2 (en) 2007-12-13 2013-09-24 Tela Innovations, Inc. Super-self-aligned contacts and method for making the same
US8225261B2 (en) 2006-03-09 2012-07-17 Tela Innovations, Inc. Methods for defining contact grid in dynamic array architecture
US7932545B2 (en) 2006-03-09 2011-04-26 Tela Innovations, Inc. Semiconductor device and associated layouts including gate electrode level region having arrangement of six linear conductive segments with side-to-side spacing less than 360 nanometers
US9563733B2 (en) 2009-05-06 2017-02-07 Tela Innovations, Inc. Cell circuit and layout with linear finfet structures
US7943967B2 (en) 2006-03-09 2011-05-17 Tela Innovations, Inc. Semiconductor device and associated layouts including diffusion contact placement restriction based on relation to linear conductive segments
US7446352B2 (en) 2006-03-09 2008-11-04 Tela Innovations, Inc. Dynamic array architecture
US7586800B1 (en) 2006-08-08 2009-09-08 Tela Innovations, Inc. Memory timing apparatus and associated methods
US8286107B2 (en) 2007-02-20 2012-10-09 Tela Innovations, Inc. Methods and systems for process compensation technique acceleration
US7979829B2 (en) * 2007-02-20 2011-07-12 Tela Innovations, Inc. Integrated circuit cell library with cell-level process compensation technique (PCT) application and associated methods
US8667443B2 (en) 2007-03-05 2014-03-04 Tela Innovations, Inc. Integrated circuit cell library for multiple patterning
US7888705B2 (en) 2007-08-02 2011-02-15 Tela Innovations, Inc. Methods for defining dynamic array section with manufacturing assurance halo and apparatus implementing the same
NZ583783A (en) * 2007-09-20 2012-10-26 Commw Scient Ind Res Org Avian interferon-lambda polypeptide and genetic sequences encoding the same
RU2486245C2 (ru) * 2007-10-15 2013-06-27 Чугаи Сейяку Кабусики Кайся Способ получения клетки, способной продуцировать гетеропротеины с высоким выходом
US8453094B2 (en) 2008-01-31 2013-05-28 Tela Innovations, Inc. Enforcement of semiconductor structure regularity for localized transistors and interconnect
US7939443B2 (en) 2008-03-27 2011-05-10 Tela Innovations, Inc. Methods for multi-wire routing and apparatus implementing same
KR101749351B1 (ko) 2008-07-16 2017-06-20 텔라 이노베이션스, 인코포레이티드 동적 어레이 아키텍쳐에서의 셀 페이징과 배치를 위한 방법 및 그 구현
US9122832B2 (en) 2008-08-01 2015-09-01 Tela Innovations, Inc. Methods for controlling microloading variation in semiconductor wafer layout and fabrication
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2239322A1 (de) * 2009-04-07 2010-10-13 Basf Se Verwendung von Enzymen zum Reduzieren von Formaldehyd aus formaldehydhaltigen Produkten
US8661392B2 (en) 2009-10-13 2014-02-25 Tela Innovations, Inc. Methods for cell boundary encroachment and layouts implementing the Same
US9159627B2 (en) 2010-11-12 2015-10-13 Tela Innovations, Inc. Methods for linewidth modification and apparatus implementing the same
EP2740485B1 (de) * 2012-12-07 2018-10-31 Brightpulse Holding LTD. Protein slurp-1 zur verwendung bei der behandlung von augenkrankheiten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359415A (en) * 1981-06-03 1982-11-16 University Of Tennessee Research Corporation Isolation of an antineoplastic protein fraction and an antineoplastic peptide fraction from human urine
US4470970A (en) * 1981-07-02 1984-09-11 Burzynski Stanislaw R Purified antineoplaston fractions and methods of treating neoplastic disease
US5298604A (en) * 1992-07-27 1994-03-29 Sloane Nathan H Parital primary amino acid sequence of the antineoplastic protein (ANUP); a cytokine present in granulocytes

Also Published As

Publication number Publication date
ITRM920919A0 (it) 1992-12-22
PT675956E (pt) 2003-07-31
IL108149A0 (en) 1994-04-12
FI953091A0 (fi) 1995-06-21
JP3025014B2 (ja) 2000-03-27
IT1257184B (it) 1996-01-10
DE69332861D1 (de) 2003-05-15
EP0675956B1 (de) 2003-04-09
IL108149A (en) 2005-05-17
ITRM920919A1 (it) 1994-06-22
NO315800B1 (no) 2003-10-27
AU690093B2 (en) 1998-04-23
RU2177480C2 (ru) 2001-12-27
DK0675956T3 (da) 2003-07-07
ATE236976T1 (de) 2003-04-15
KR950704486A (ko) 1995-11-20
FI114478B (fi) 2004-10-29
NO952494D0 (no) 1995-06-21
WO1994014959A1 (en) 1994-07-07
KR100193107B1 (ko) 1999-06-15
FI116059B (fi) 2005-09-15
ES2193152T3 (es) 2003-11-01
US5908827A (en) 1999-06-01
NO952494L (no) 1995-08-21
UA46702C2 (uk) 2002-06-17
AU5833594A (en) 1994-07-19
CA2151156A1 (en) 1994-07-07
EP0675956A1 (de) 1995-10-11
ZA939621B (en) 1995-06-22
FI953091A (fi) 1995-06-21
JPH08509359A (ja) 1996-10-08
FI20040608A (fi) 2004-04-29

Similar Documents

Publication Publication Date Title
DE69332861D1 (de) Neues protein aus urin, komponent b genannt
EE9900481A (et) Väikesed molekulid, mida kasutatakse põletikuliste haiguste raviks
DE68929387T2 (de) Interleukin-1-Inhibitoren
ATE89262T1 (de) Neue alpha-aminoacetophenone als photoinitiatoren.
DE69528829D1 (de) Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
DK0473671T3 (da) Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
FI943550A0 (fi) Suihkujäädytetty nabumetoni
ES2193144T3 (es) Compuestos de dna que comprenden secuencias que codifican manuronano c-5-epimerasa.
ES2131528T3 (es) Nuevos polipeptidos y su uso.
DK0639275T3 (da) Hidtil ukendte GABAa-receptorundertyper og fremgangsmåder til screening af lægemiddelforbindelser under anvendelse af imidazoquinoxaliner og pyrrolopyimidiner til binding til GABAa-receptorundertyper
ATE213776T1 (de) (s)-hydroxynitrillyase aus hevea brasiliensis
DK0589949T3 (da) Hidtil ukendte peptider, fremgangsmåder til fremstilling heraf og anvendelse af disse
DE69418035D1 (de) Hiv-proteaseinhibitoren
SE9600120D0 (sv) Novel medical use
SE9600086D0 (sv) New manufacturing process
ES2163001T3 (es) Nuevos derivados de borneol, procedimiento para su preparacion y su utilizacion farmaceutica.
DK0937094T3 (da) Fremgangsmåde til fremstilling af ivermectin
DE59611353D1 (de) Transketolase-verwandtes protein
ES2098119T3 (es) Nuevas triazoloquinazolinas, su obtencion y empleo.
NO974687D0 (no) Kondenserte <beta>-carboliner
ATE160782T1 (de) Fluoro-nukleosid-reinigung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: LABORATOIRES SERONO S.A., COINSINS, VAUD, CH

8339 Ceased/non-payment of the annual fee